Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib at the 16th Congress of the European Hematology Association

Onyx Pharmaceuticals ONXX today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 16th Congress of the European Hematology Association Annual Meeting, June 9-12, 2011 in London, UK. "Data being presented this week at EHA continue to demonstrate the strength of clinical evidence for carfilzomib, including the final results from the 005 study, showing promising activity and, importantly, tolerability in patients with renal dysfunction," said Ted W. Love, MD., Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals. "Beyond EHA, we are enrolling patients in the Phase 3 FOCUS trial of carfilzomib in relapsed and refractory myeloma to support a filing with the European Medicines Agency. We also remain on track for filing a new drug application in the U.S. under the accelerated approval process in the July to August timeframe."